The Lumir Mission aims to help over 1 million patients worldwide by contributing to the scientific evidence-base of medicinal cannabis through a range of research activities.
The Lumir Mission aims to help over 1 million patients worldwide by contributing to the scientific evidence-base of medicinal cannabis through a range of research activities.
| What is the Lumir Mission Study About?
The Lumir Mission Study aims to understand patient experiences with different types of medicinal cannabis products and what characteristics of medicinal cannabis products are associated with better outcomes, for a range of medical conditions and associated symptoms (e.g. terpene content, ratios and amount of THC, CBD and other minor cannabinoids).
This will help guide the future development of new cannabis products, targeted to specific conditions or symptoms. This information will allow consumers and doctors to make confident and informed decisions regarding choice of medicinal cannabis products best suited for their condition.
This study aims to collect real-world data from one million medicinal cannabis users to give valuable understanding to these questions.
What is the Lumir Mission Study About?
The Lumir Mission Study aims to understand patient experiences with different types of medicinal cannabis products and what characteristics of medicinal cannabis products are associated with better outcomes, for a range of medical conditions and associated symptoms (e.g. terpene content, ratios and amount of THC, CBD and other minor cannabinoids).
This will help guide the future development of new cannabis products, targeted to specific conditions or symptoms. This information will allow consumers and doctors to make confident and informed decisions regarding choice of medicinal cannabis products best suited for their condition.
This study aims to collect real-world data from tens of thousands of medicinal cannabis users to give valuable understanding to these questions.
Download the Lumir Mission app to join our global research study
Help us understand what treatments work best for your condition.
Download the Lumir Mission app to join our global research study
Help us understand what treatments work best for your condition.
| Who Can Participate in The Study?
All participants must be using medicinal cannabis for a health complaint
Aged 18 years and over
In Australia, all medicinal cannabis products are available by prescription-only.
Aged 18 years and over
In the UK, medicines containing tetrahydrocannabinol (THC) are available by prescription-only.
Aged 21 years and over
Who Can Participate in The Study?
All participants must be using medicinal cannabis for a health complaint
Aged 18 years and over
In Australia, all medicinal cannabis products are available by prescription-only.
Aged 18 years and over
In the UK, medicines containing tetrahydrocannabinol (THC) are available by prescription-only.
Aged 21 years and over
| How Do I Join the Study?
Read the Participant Information Form
To participate, you need to have read the Participant Information Form specific for your region.
Download the Lumir Mission app
Scan the QR code or visit the relevant app store for your device
USA
For advice:
FREECALL 888-716-4896 and speak with a Care Coach at the Lumir Clinic
How Do I Join the Study?
Read the Participant Information Form
To participate, you need to have read the Participant Information Form specific for your region.
Download the Lumir Mission app
Scan the QR code or visit the relevant app store for your device
USA
For advice:
FREECALL 888-716-4896 and speak with a Care Coach at the Lumir Clinic
| Who is Conducting the Study?
This study is sponsored by Cannim Group Pty Ltd, a medicinal cannabis company based in Australia, with business interests in the US, UK, Canada, Jamaica and Germany.
Prof Kylie O’Brien
Chief Investigator
Australia, US and UK
Professor Kylie O’Brien PhD
Chief Scientific Officer,
Cannim Group Pty Ltd
Adjunct Professor Torrens University and Adjunct Fellow NICM Health Research Institute, Western Sydney University)
Dr Anup Mathew
Chief Investigator UK
Assoc. Investigator Aust/US
Dr Anup Mathew MD, MA, MSc, BSc (Hons), FRCPsych, FHEA, DCP, MDCH, DCBH, PGCDM, PGCCE, MAcadMEd
Medical Director Cannim UK, Consultant Psychiatrist
Who is Conducting the Study?
This study is sponsored by Cannim Group Pty Ltd, a medicinal cannabis company based in Australia, with business interests in the US, UK, Canada, Jamaica and Germany.
Prof Kylie O’Brien
Chief Investigator
Australia, US and UK
Professor Kylie O’Brien PhD
Chief Scientific Officer,
Cannim Group Pty Ltd
Adjunct Professor Torrens University and Adjunct Fellow NICM Health Research Institute, Western Sydney University)
Dr Anup Mathew
Chief Investigator UK
Assoc. Investigator Aust/US
Dr Anup Mathew MD, MA, MSc, BSc (Hons), FRCPsych, FHEA, DCP, MDCH, DCBH, PGCDM, PGCCE, MAcadMEd
Medical Director Cannim UK, Consultant Psychiatrist
Your journey
matters
SHARE YOUR EXPERIENCE WITH US
Your journey matters
SHARE YOUR EXPERIENCE WITH US
